Our results suggest that patients with anti-GBM disease combined with mesangial IgA deposition have higher 24-hour urine protein excretion at diagnosis (p=0.02), less incidence of oliguria or anuria (p=0.03), lower SCr levels at diagnosis(p=0.002), and better renal prognosis (p<0.001) than patients with classical anti-GBM disease. This evidence concerns the gene CD79A and glioblastoma.